NCT00780663

Quarfloxin in Patients With Low to Intermediate Grade Neuroendocrine Carcinoma

A Phase 2, Multi-Center, Open Label Study Evaluating the Efficacy and Safety of Quarfloxin in Patients With Low to Intermediate Grade Neuroendocrine Carcinoma

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 25 (estimated)
• Sponsor: Cylene Pharmaceuticals · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a Phase 2, open-label, multicenter, efficacy and safety study of quarfloxin in patients with low or intermediate grade neuroendocrine cancer. The purpose of this study is to evaluate the rate of clinical benefit response to quarfloxin treatment including the reduction in secretory symptoms of flushing and/or diarrhea or the reduction quantifiable hormones or other biochemical tumor markers.

Conditions

• Neuroendocrine Tumors
• Carcinoid Tumor

Interventions

Type	Name	Description
DRUG	Quarfloxin	IV Quarfloxin 240 mg/m2 daily x5 days every 21 days

Timeline

• Start date: 2008-10-01
• Primary completion: 2010-03-01
• Completion: 2010-03-01
• First posted: 2008-10-28
• Last updated: 2011-06-15

Locations

13 sites across 1 country: United States